Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T13:26:38.056Z.
Calculation as of: 2026-10-06T13:26:38.056Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5aadd97284981d173c87413c67de95801d58f7ce8cc73935cbfc70b12a62615a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$1.75B
EBITDA Yield
6.23%
TTM Avg
1.74%
3Y Avg
1.49%
5Y Avg
1.49%
Market Cap
$1.71B
EBITDA Yield
22.55%
TTM Avg
15.05%
3Y Avg
6.70%
5Y Avg
7.30%
Market Cap
$1.89B
EBITDA Yield
0.59%
TTM Avg
0.62%
3Y Avg
0.49%
5Y Avg
0.49%
Market Cap
$1.66B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.66B
EBITDA Yield
14.48%
TTM Avg
10.69%
3Y Avg
8.08%
5Y Avg
6.99%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Generate Biomedicines, Inc. (GENB) | $1.78B | N/A | N/A | N/A | N/A |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.78B | N/A | N/A | N/A | N/A |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.75B | 6.23% | 1.74% | 1.49% | 1.49% |
| Astrana Health, Inc. (ASTH)vs › | $1.83B | 7.44% | 5.95% | 6.07% | 6.49% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | 22.55% | 15.05% | 6.70% | 7.30% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.88B | N/A | N/A | N/A | N/A |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 0.59% | 0.62% | 0.49% | 0.49% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.66B | N/A | N/A | N/A | N/A |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.66B | 14.48% | 10.69% | 8.08% | 6.99% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.65B | 1.74% | 1.16% | 1.16% | 1.16% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
